Racial and Ethnic Differences in Adjuvant Hormonal Therapy Use

Livaudais, Jennifer C.; Li, Christopher; John, Esther M.; Terry, Mary Beth; Daly, Mary; Buys, Saundra S.; Habel, Laurel A.; Thompson, Beti; Yanez, N. David; Coronado, Gloria D.

doi:10.1089/jwh.2011.3254

Cited by 7 publications

(6 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Specifically, study suggests that African-Americans are primarily and persistently at higher risk of death only for HR+/HER2- breast cancers at Stages II and III, for which breast cancers respond favorably to anti-endocrine therapy or trastuzumab therapy (37). This underscores the central role of treatment in the black/white disparity in breast cancer, even though no race/ethnicity differences in adjuvant hormone therapy use were identified in two recent studies (38, 39). Unfortunately, information on endocrine therapies is under-captured in cancer registry data, and specific information regarding receipt of trastuzumab is not reported.…”

Section: Discussionmentioning

confidence: 73%

Breast Cancer Mortality in African-American and Non-Hispanic White Women by Molecular Subtype and Stage at Diagnosis: A Population-Based Study

Gomez

Keegan

et al. 2015

Cancer Epidemiology, Biomarkers &Amp; Prevention

100

View full text Add to dashboard Cite

Background Higher breast cancer mortality rates for African-American than non-Hispanic white women are well documented; however, it remains uncertain if this disparity occurs in disease subgroups defined by tumor molecular markers and stage at diagnosis. We examined racial differences in outcome according to subtype and stage in a diverse, population-based series of 103,498 patients. Methods We obtained data for all invasive breast cancers diagnosed 1/1/2005-12/31/2012 and followed through 12/31/2012 among 93,760 non-Hispanic white and 9,738 African-American women in California. Molecular subtypes were categorized according to tumor expression of hormone receptor (HR, based on estrogen and progesterone receptors) and human epidermal growth factor receptor 2 (HER2). Cox proportional hazards models were used to calculate hazard ratios (HR) and 95% confidence intervals (CI) for breast cancer-specific mortality. Results After adjustment for patient, tumor and treatment characteristics, outcomes were comparable by race for Stage I or IV cancer regardless of subtype, and HR+/HER2+ or HR-/HER2+ cancer regardless of stage. We found substantially higher hazards of breast cancer death among African-American women with Stage II/III HR+/HER2- (HR, 1.31, 95% CI, 1.03-1.65, and HR, 1.39, 95% CI, 1.10-1.75, respectively) and Stage III triple-negative cancers relative to whites. Conclusions There are substantial racial/ethnic disparities among patients with Stages II/III HR+/HER2- and Stage III triple-negative breast cancers but not for other subtype and stage. Impact These data provide insights to assess barriers to targeted treatment (e.g. trastuzumab or endocrine therapy) of particular subtypes of breast cancer among African-American patients.

show abstract

Section: Discussionmentioning

confidence: 73%

Breast Cancer Mortality in African-American and Non-Hispanic White Women by Molecular Subtype and Stage at Diagnosis: A Population-Based Study

Gomez

Keegan

et al. 2015

Cancer Epidemiology, Biomarkers &Amp; Prevention

100

View full text Add to dashboard Cite

show abstract

“…84 This same study demonstrated that racial/ethnic differences in ET use decreased as the diffusion of ET into clinical practice increased over time. 84 …”

Section: Resultsmentioning

confidence: 85%

“…Eight studies 19,22,60,79,82,83,85,87 used large secondary data sources or medical records to examine racial/ethnic and socioeconomic disparities in ET use; of these, 3 77,79,86 examined adjuvant breast cancer therapy broadly, including not only ET use but also either chemotherapy, or chemotherapy with radiation therapy. Although these studies evaluated chemotherapy and radiation therapy as dependent variables, some studies included these treatment variables (i.e., surgery, chemotherapy, radiation) as predictor variables of ET use 19,22,60,81,82,84,87 and other studies 78,80,83 , did not include treatment variables in their analyses. One study stratified results by chemotherapy receipt.…”

Section: Resultsmentioning

confidence: 99%

Racial/Ethnic and Socioeconomic Disparities in Endocrine Therapy Adherence in Breast Cancer: A Systematic Review

2015

View full text Add to dashboard Cite

We examined the current literature to understand factors that influence endocrine therapy (ET) adherence among racial/ethnic and socioeconomic subpopulations of breast cancer patients. We searched PubMed and PsycINFO databases for studies from January 1, 1978, to June 20, 2014, and January 1, 1991, to June 20, 2014, respectively, and hand-searched articles from relevant literature reviews. We abstracted and synthesized results within a social ecological framework. Fourteen articles met all inclusion criteria. The majority of included articles reported significant underuse of ET among minority and low-income women. Modifiable intrapersonal, interpersonal, and community-level factors are associated with ET use, and these factors vary across subgroups. Both race/ethnicity and socioeconomic status are associated with ET use in most settings. Variation in factors associated with ET use across subgroups indicates the need for more nuanced research and targeted interventions among breast cancer patients.

show abstract

“…Demographics, healthcare factors, patient-provider communication, and social support have been associated with AHT adherence (e.g. Livaudais et al, 2012; Murphy, Bartholomew, Carpentier, Bluethmann, & Vernon, 2012). As social support is expanded online, breast cancer survivors are more likely to seek support on OSGs (Davison, Pennebaker, & Dickerson, 2000).…”

Section: Tamoxifenmentioning

confidence: 99%

Sentiment Analysis of an Online Breast Cancer Support Group: Communicating about Tamoxifen

Cabling

Turner

Hurtado‐de‐Mendoza

et al. 2017

Health Communication

View full text Add to dashboard Cite

A better understanding of the breast cancer online narrative is important for a clearer conceptualizing of the role of online platforms in mediating health related support. Sentiment analysis was conducted on a breast cancer online support group regarding Tamoxifen to understand users’ emotions and opinions. This analysis was then contextualized within online social support literature. Out of the 498 users, the most active users were 80% more positive than least active users while least active users were 48% more negative than most active ones; both differences were statistically significant. The higher the stage of cancer a user had, the less likelihood that she would have posted, and if she were to post, the post would have focused on her side effects and the anxiety/sadness that tailgates those side effects. The lower the stage of cancer a user had, the more likelihood that she would have posted, and additionally remained active on the forum and encouraged more (online) social support. This finding suggests that the online support platform may provide a context that exacerbates support for like-minded users where stronger ties are created around a specific sentiment within the community with less connection from those with dissimilar sentiments to the dominant group.

show abstract

Racial and Ethnic Differences in Adjuvant Hormonal Therapy Use

Cited by 7 publications

References 24 publications

Breast Cancer Mortality in African-American and Non-Hispanic White Women by Molecular Subtype and Stage at Diagnosis: A Population-Based Study

Breast Cancer Mortality in African-American and Non-Hispanic White Women by Molecular Subtype and Stage at Diagnosis: A Population-Based Study

Racial/Ethnic and Socioeconomic Disparities in Endocrine Therapy Adherence in Breast Cancer: A Systematic Review

Sentiment Analysis of an Online Breast Cancer Support Group: Communicating about Tamoxifen

Contact Info

Product

Resources

About